Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.137?

Hybridoma

Volumn 16, Issue 1, 1997, Pages 59-63

  Reinsberg, Jochen ^a   Krebs, Dieter ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CA 125 ANTIGEN; IMACIS 2; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OC 125; OREGOVOMAB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CROSS REACTION; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030973707     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.59     Document Type: Conference Paper

References (12)

1. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, and Sears HF: Human anti-idiotypic antibodies in cancer patients: Is the modulation of the immune response beneficial for the patients? Proc Natl Acad Sci USA 1984;81:216-219.
2. Courtenay-Luck NS, Epenetos AA, Sivolapenko BG, Larche M, Barkans JR, and Ritter, MA: Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;15:894-897.
3. Wagner U, Reinsberg J, Oehr P, Briele B, Schmidt, S, Werner A, Krebs, D, and Bierack HJ: Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen. Tumordiagn Ther 1990;11:1-4.
4. 1). Relation to the clinical outcome-an important antitumoral effector function? Hybridoma 1991;10:421-426.
5. Schmolling J, Reinsberg J, Wagner U, and Krebs D: Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Hybridoma 1995;14:183-186.
6. Bast RC, Freeney M, Lazarus H, Nadler LM, Colvin RB, and Knapp RC: Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337.
7. Kabawat SE, Bast RC, Welch WR, Knapp RC, and Colvin RB: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983;79:98-104.
8. Krantz MJ, MacLean G, Longenecker BM, and Suresh MR. A radioimmunoassay for CA 125 employing two new monoclonal antibodies (Abstract). J Cell Biochem 1988;Suppl 12E:139.
9. Wagner U, Oehr P, Reinsberg J, Schmidt S, Schlebusch H, Werner A, and Krebs D: Immunotherapy of advanced ovarian carcinomas by the activation of the idiotypic network. Biotech Therapeutics 1992;3:81-89.
10. Reinsberg, J, Schmolling J, and Ackerman D: A simple and sensitive assay for determination of human anti-idiotypic anti-B72.3 antibodies not affected by TAG-72. Eur J Clin Chem Clin Biochem 1996;34:237-244.
11. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, and Noujaim AA: Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 1995;14:199-203.
12. Bhattacharya-Chatterjee M, Foon KA, and Köhler H: Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 1994;38:75-82.